Viking Therapeutics VKTX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's change in accrued liabilities?
- Viking Therapeutics (VKTX) reported change in accrued liabilities of $15.86M in Q1 2026.
- How has Viking Therapeutics's change in accrued liabilities changed year-over-year?
- Viking Therapeutics's change in accrued liabilities increased by 376.4% year-over-year, from -$5.74M to $15.86M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.